Biocon Ltd
About
Biocon is a pharmaceutical company founded in India with a major aim to find ways to treat cancer, diabetes, and autoimmune diseases. Its 4 primary business verticals—generics, biosimilars, novel biologics, and biosimilars—are present in more than 120 countries all over the world. Biocon co-develops insulin analogues and biosimilar antibodies in partnership with Viatris. Its partnership with Sandoz, a Novartis division, assists in the production of biosimilars for oncology and immunology. The company has also formed an alliance with Serum Institute Life Sciences (SILS) to develop vaccines and antibodies against infectious diseases. Its production of ADG20, an antibody working against the spike protein of the coronavirus, in partnership with Adagio Therapeutics of the US, was influential in keeping the COVID rise in check. Though headquartered in Bangalore, Biocon operates through offices in locations like the US, UK, Ireland, Greece, and Malaysia internationally.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 16478 40.8% | 11704 35.3% | 8653 12.4% | 7700 14.4% | 6730 11.0% | 6064 38.1% | 4393 6.3% | 4134 10.0% | 3757 12.8% | 3330 13.5% | 2933 6.0% | 2766 26.2% | 2193 13.6% | 1931 -20.9% | 2442 41.2% | 1730 - |
| Net Operating Income (INR Cr) | 14756 32.05% | 11174 36.54% | 8184 14.57% | 7143 13.37% | 6301 14.26% | 5514 33.73% | 4123 5.97% | 3891 16.24% | 3347 8.34% | 3090 7.39% | 2877 15.77% | 2485 19.11% | 2087 15.53% | 1806 -23.73% | 2368 47.19% | 1609 52.59% |
| Profit (INR Cr) | 1023 121.0% | 463 -28.6% | 648 -12.4% | 741 -1.0% | 748 -17.4% | 905 143.1% | 372 -39.2% | 612 11.2% | 550 10.7% | 497 20.2% | 414 -18.7% | 509 50.4% | 338 -7.9% | 368 25.3% | 293 214.9% | 93 - |
| Assets (INR Cr) | 43172 -5.5% | 45670 161.9% | 17440 11.2% | 15685 32.8% | 11816 17.7% | 10035 20.6% | 8323 5.2% | 7910 9.9% | 7198 40.4% | 5127 11.9% | 4584 31.4% | 3488 11.4% | 3130 14.1% | 2744 19.0% | 2305 11.9% | 2059 - |
| Net Worth (INR Cr) | 19783 10.7% | 17866 111.9% | 8432 10.6% | 7626 13.7% | 6705 10.0% | 6097 17.7% | 5180 7.1% | 4837 19.9% | 4033 23.3% | 3270 8.1% | 3026 12.3% | 2694 18.6% | 2272 11.8% | 2032 15.7% | 1757 16.4% | 1510 1.8% |
| Employee Cost (INR Cr) | 2664 22.2% | 2181 16.0% | 1880 8.0% | 1741 19.3% | 1459 25.2% | 1165 25.2% | 931 24.7% | 747 22.4% | 610 7.6% | 567 18.0% | 481 23.4% | 389 26.6% | 308 28.8% | 239 -2.5% | 245 35.3% | 181 - |
| Interest Cost (INR Cr) | 974 | 419 | 68 | 58 | 65 | 71 | 62 | 26 | 29 | 9 | 2 | 8 | 12 | 23 | 17 | 18 |
| Cash & Bank Balance (INR Cr) | 2259 | 2400 | 1748 | 2015 | 999 | 1057 | 1323 | 1044 | 1539 | 938 | 804 | 673 | 523 | 442 | 140 | 12 |
| Total Debt (INR Cr) | 16277 | 18019 | 5147 | 4481 | 2715 | 2422 | 2264 | 2303 | 2478 | 1117 | 864 | 267 | 271 | 334 | 514 | 524 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 6.2% | 4.0% | 7.5% | 9.6% | 11.1% | 14.9% | 8.5% | 14.8% | 14.7% | 14.9% | 14.1% | 18.4% | 15.4% | 19.0% | 12.0% | 5.4% |
| Profit As % Of Assets | 2.4% | 1.0% | 3.7% | 4.7% | 6.3% | 9.0% | 4.5% | 7.7% | 7.7% | 9.7% | 9.0% | 14.6% | 10.8% | 13.4% | 12.7% | 4.5% |
| Profit As % Of Networth | 5.2% | 2.6% | 7.7% | 9.7% | 11.2% | 14.9% | 7.2% | 12.7% | 13.7% | 15.2% | 13.7% | 18.9% | 14.9% | 18.1% | 16.7% | 6.2% |
| Interest Cost to EBITDA % | 30.4% | 20.4% | 4.1% | 3.7% | 4.1% | 5.1% | 7.4% | 2.7% | 4.4% | 1.3% | 0.3% | 1.5% | 2.4% | 4.4% | 3.6% | 10.6% |
| Debt to Equity Ratio | 0.82 | 1.01 | 0.61 | 0.59 | 0.40 | 0.40 | 0.44 | 0.48 | 0.61 | 0.34 | 0.29 | 0.10 | 0.12 | 0.16 | 0.29 | 0.35 |
| RONW | 6.9% | 6.6% | 10.8% | 11.8% | 13.6% | 14.6% | 9.1% | 15.5% | 11.1% | 14.0% | 15.1% | 13.8% | 15.6% | 19.4% | 18.2% | 16.2% |
| ROCE | 6.4% | 5.7% | 7.6% | 8.7% | 12.2% | 12.4% | 8.7% | 12.1% | 8.6% | 11.1% | 13.6% | 12.6% | 13.8% | 18.6% | 16.9% | 14.7% |